Advertisement

Vaccines in Rheumatic Diseases

  • Carlos Pineda
  • Carina Soto-Fajardo
  • Julio Granados
Chapter

Abstract

Vaccination is one of the most important public health strategies to prevent infectious diseases, reduce their severity, or prevent the complications thereof, thus decreasing morbidity and mortality in vulnerable groups such as patients with autoimmune inflammatory rheumatic diseases (AIRD).

Patients with AIRD entertain an increased risk of acquiring infections, as well as an increase in the morbidity and mortality associated with these infections, by immunosuppression due to their underlying condition, their comorbidities, and the immunosuppressive treatment. In addition to this, the immunomodulatory medications can modify the effectiveness of vaccines; therefore, it is important that the rheumatologist not only understand the efficacy and safety of each vaccine but also the appropriate time for their prescription.

This chapter focuses on the indications, contraindications, and efficacy of the vaccines included in the adult vaccination schedules of patients with AIRD, as well as special considerations such as schemes for patients traveling abroad.

Keywords

Vaccine Rheumatic diseases Primary prevention Rheumatoid arthritis Systemic lupus erythematous Infection diseases Influenza Pneumococcal pneumonia Shingles Human papillomavirus Hepatitis B virus Corticosteroids Disease modifying anti-rheumatic drugs (DMARDs) Biologics 

Abbreviations

ACR

American College of Rheumatology

AIRD

Autoimmune inflammatory rheumatic diseases

Anti-HBs ab

Antibodies against the HBV surface antigens

BCG

Bacillus Calmette-Guérin

CDC

Centers for Disease Control and Prevention

CI

Confidence interval

COMORA

Comorbidities in rheumatoid arthritis

CS

Corticosteroids

DMARDs

Disease-modifying anti-rheumatic drugs

DTaP

Diphtheria, tetanus, and pertussis vaccine

EULAR

European League Against Rheumatism

HBV

Hepatitis B virus

Hib

Haemophilus influenzae type b

HIV

Human immunodeficiency virus

HPV

Human papillomavirus

IDSA

Infectious Diseases Society of America

IPD

Invasive pneumococcal disease

(MenACWY)

Polysaccharide and conjugate against serogroups A, C, W, and Y meningococcal vaccine

MenB

Recombinant vaccine against serogroup B of meningococcus

MMR

Measles, mumps, and rubella vaccine

MTX

Methotrexate

PCV13

13-Valent pneumococcal conjugate vaccine

PPV23

23-Valent polysaccharide vaccine

RA

Rheumatoid arthritis

RR

Relative risk

RZV

Recombinant zoster vaccine

SLE

Systemic lupus erythematous

SS

Systemic sclerosis

TB

Tuberculosis

Td

Tetanus/diphtheria

TNFi

Tumoral necrosis factor inhibitors

UK

United Kingdom

VZV

Varicella zoster virus

YEL-AND

Yellow fever vaccine-associated neurologic disease

YEL-AVD

Yellow fever vaccine-associated viscerotropic disease

ZVL

Zoster vaccine live

References

  1. 1.
    Papadopoulou D, Tsoulas C, Tragiannidis A, Sipsas NV. Role of vaccinations and prophylaxis in rheumatic diseases. Best Pract Res Clin Rheumatol [Internet]. 2015;29(2):306–18. Available from:  https://doi.org/10.1016/j.berh.2015.02.001.CrossRefGoogle Scholar
  2. 2.
    Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317–28.PubMedGoogle Scholar
  3. 3.
    Van Assen S, Elkayam O, Agmon-levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-im. Autoimmun Rev [Internet]. 2011;10(6):341–52. Available from:  https://doi.org/10.1016/j.autrev.2010.12.003.CrossRefGoogle Scholar
  4. 4.
    Ada G. Overview of vaccines and vaccination. Mol Biotechnol. 2005;29(3):255–71.CrossRefGoogle Scholar
  5. 5.
    Mackay IR, Rosen FS. Vaccines and vaccination. N Engl J Med. 2001;345(14):1042–53.CrossRefGoogle Scholar
  6. 6.
    Siegrist C-A. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines [Internet]: Sixt. W.B. Saunders; 2013. p. 14–32. Available from: http://linkinghub.elsevier.com/retrieve/pii/B9781455700905000045.
  7. 7.
    Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.CrossRefGoogle Scholar
  8. 8.
    Wong PKK, Bagga H, Hanrahan P. A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. Intern Med J. 2017;47(5):491–500.CrossRefGoogle Scholar
  9. 9.
    Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(8):431.CrossRefGoogle Scholar
  10. 10.
    Cordeiro I, Duarte A, Ferreira J, Goncalves M, Meirinhos T, Rocha T, et al. Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology. Acta Reumatol Port. 2016;41:112–30.PubMedGoogle Scholar
  11. 11.
    Van Assen S, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22.CrossRefGoogle Scholar
  12. 12.
    Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, et al. Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol. 2018;24(3):138–47.PubMedGoogle Scholar
  13. 13.
    Westra J, Rondaan C, Van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol [Internet]. 2015;11(3):135–45. Available from:  https://doi.org/10.1038/nrrheum.2014.206.CrossRefGoogle Scholar
  14. 14.
    Müller-Ladner C, Müller-Ladner U. Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology topical collection on infections and arthritis. Curr Rheumatol Rep. 2013;15(6):330.CrossRefGoogle Scholar
  15. 15.
    Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28(3):330–6.CrossRefGoogle Scholar
  16. 16.
    Huang Y, Wang H, Wan L, Lu X, Tam WWS. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (United States). 2016;95(19):1–7.Google Scholar
  17. 17.
    Milanovic M, Stojanovich L, Djokovic A, Kontic M, Gvozdenovic E. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med. 2013;229(1):29–34.CrossRefGoogle Scholar
  18. 18.
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. 2011;63(7):1062–7.CrossRefGoogle Scholar
  19. 19.
    Saad CGS, Borba EF, Aikawa NE, Silva CA, Pereira RMR, Calich AL, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis. 2011;70(6):1068–73.CrossRefGoogle Scholar
  20. 20.
    Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2007;17(6):531–3.CrossRefGoogle Scholar
  21. 21.
    Kapetanovic MC, Saxne T, Nilsson J-A, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology [Internet]. 2006;46(4):608–11. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kel366.CrossRefGoogle Scholar
  22. 22.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum [Internet]. 2010;39(6):442–7. Available from:  https://doi.org/10.1016/j.semarthrit.2008.12.002.CrossRefGoogle Scholar
  23. 23.
    Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81.CrossRefGoogle Scholar
  24. 24.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis. 2006;65(2):191–4.CrossRefGoogle Scholar
  25. 25.
    Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza vaccine and autoimmunity. Isr Med Assoc J. 2009;11(3):183–5.PubMedGoogle Scholar
  26. 26.
    Abu-Shakra M, Press J, Buskila D, Sukenik S. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun Rev. 2007;6(8):543–6.CrossRefGoogle Scholar
  27. 27.
    Müller RB, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, et al. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol. 2013;31(5):723–30.PubMedGoogle Scholar
  28. 28.
    Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology. 2009;48(10):1294–9.CrossRefGoogle Scholar
  29. 29.
    Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine [Internet]. 2015;33(12):1446–52. Available from:  https://doi.org/10.1016/j.vaccine.2015.01.065.CrossRefGoogle Scholar
  30. 30.
    Shelton CM, Gray MD, Crill CM. To mist or not to mist: an update on the recommendations for live-attenuated influenza vaccine. J Am Pharm Assoc [Internet]. 2018;58(4):457–9. Available from:  https://doi.org/10.1016/j.japh.2018.06.005.CrossRefGoogle Scholar
  31. 31.
    Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res [Internet]. 2016;16(1):1–10. Available from:  https://doi.org/10.1186/s12913-016-1432-4.
  32. 32.
    Bahuaud M, Beaudouin-Bazire C, Husson M, Molto A, Launay O, Batteux F, et al. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2018;14(6):1464–70.CrossRefGoogle Scholar
  33. 33.
    Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33(4):283–8.CrossRefGoogle Scholar
  34. 34.
    Thomas K, Vassilopoulos D. Immunization in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol [Internet]. 2016;30(5):946–63. Available from:  https://doi.org/10.1016/j.berh.2016.10.009.CrossRefGoogle Scholar
  35. 35.
    Broyde A, Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D, et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol. 2016;43(2):267–72.CrossRefGoogle Scholar
  36. 36.
    Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) [Internet]. 2014;66(7):1016–26. Available from: http://doi.wiley.com/10.1002/acr.22246.CrossRefGoogle Scholar
  37. 37.
    Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther [Internet]. 2015;17(1):149. Available from: http://arthritis-research.com/content/17/1/149.CrossRefGoogle Scholar
  38. 38.
    Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther [Internet]. 2015;17(1):1–10. Available from:  https://doi.org/10.1186/s13075-015-0863-3.
  39. 39.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefGoogle Scholar
  40. 40.
    Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: a meta-analysis. Microb Pathog [Internet]. 2018;114:436–43. Available from:  https://doi.org/10.1016/j.micpath.2017.12.014.CrossRefGoogle Scholar
  41. 41.
    Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, et al. Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine [Internet]. 2017;84(5):525–30. Available from:  https://doi.org/10.1016/j.jbspin.2017.05.013.CrossRefGoogle Scholar
  42. 42.
    Centers for Diseace Control and Prevention. Hepatitis B. Epidemiol Prev Vaccine-Prev Dis. 2015;(November):149–74.Google Scholar
  43. 43.
    Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev [Internet]. 2012;11(8):572–6. Available from:  https://doi.org/10.1016/j.autrev.2011.10.015.CrossRefGoogle Scholar
  44. 44.
    Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(7):623–5.CrossRefGoogle Scholar
  45. 45.
    Nelson NP. Hepatitis A. In: Brunette GW, editor. CDC yellow book. New York: Oxford University Press; 2018.Google Scholar
  46. 46.
    Rosdahl A, Herzog C, Frösner G, Norén T, Rombo L, Askling HH. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – a prospective, open-label, multi-center study. Travel Med Infect Dis [Internet]. 2018;21(August):43–50. Available from:  https://doi.org/10.1016/j.tmaid.2017.12.004.CrossRefGoogle Scholar
  47. 47.
    Bühler S, Visser LG. Hepatitis A vaccination in patients with rheumatic diseases and drug-induced immunosuppression. Travel Med Infect Dis. 2014;12(2):115–7.CrossRefGoogle Scholar
  48. 48.
    Askling HH, Rombo L, Van Vollenhoven R, Hallén I, Thörner Å, Nordin M, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014;12(2):134–42.CrossRefGoogle Scholar
  49. 49.
    Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. Hum Vaccin Immunother [Internet]. 2019;15(1):45–8. Available from: https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1514228.CrossRefGoogle Scholar
  50. 50.
    Wong KK, Burdette E, Mahon BE, Mintz ED, Ryan ET, Reingold AL. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep [Internet]. 2017;66(18):482–5. Available from: http://www.cdc.gov/mmwr/volumes/66/wr/mm6618a6.htm.CrossRefGoogle Scholar
  51. 51.
    Grein IHR, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in systemic lupus erythematosus patients: what we really should know. Pediatr Rheumatol [Internet]. 2016;14(1):10–7. Available from:  https://doi.org/10.1186/s12969-016-0072-x.
  52. 52.
    Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep [Internet]. 2014;63(RR-05):1–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25167164.Google Scholar
  53. 53.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;2018(5):1–241.Google Scholar
  54. 54.
    Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37.CrossRefGoogle Scholar
  55. 55.
    Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57.CrossRefGoogle Scholar
  56. 56.
    Kim SC, Feldman S, Moscicki A-B. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology [Internet]. 2018;57(suppl_5):v26–33. Available from: https://academic.oup.com/rheumatology/article/57/suppl_5/v26/5076149.CrossRefGoogle Scholar
  57. 57.
    Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32(9):1301–7.CrossRefGoogle Scholar
  58. 58.
    Martínez-Lavín M. HPV vaccination syndrome: a clinical mirage, or a new tragic fibromyalgia model. Reumatol Clin [Internet]. 2018;14(4):211–4. Available from:  https://doi.org/10.1016/j.reuma.2018.01.014.CrossRefGoogle Scholar
  59. 59.
    Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep [Internet]. 2016;65(49):1405–8. Available from: http://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm.CrossRefGoogle Scholar
  60. 60.
    Petrosky E, Bocchini JA, Hariri S, Cheesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep [Internet]. 2015;64(11):300–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25811677.Google Scholar
  61. 61.
    Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(4):1–34.Google Scholar
  62. 62.
    Liang J, Tiwari T, Moro P, Messonnier M, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2018;67(2):1–44.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Kim DK, Riley LE, Hunter P, Bridges CB, Woods LD, Wilson A, et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann Intern Med. 2018;168(3):210–20.CrossRefGoogle Scholar
  64. 64.
    Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep [Internet]. 2014;63(RR-01):1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24572654.Google Scholar
  65. 65.
    Jean K, Donnelly CA, Ferguson NM, Garske T. A meta-analysis of serological response associated with yellow fever vaccination. Am J Trop Med Hyg. 2016;95(6):1435–9.CrossRefGoogle Scholar
  66. 66.
    Centers for Disease Control and Prevention. In: Brunette GW, editor. CDC yellow book health information for international travel [Internet]. New York: Oxford University Press; 2017. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2018/table-of-contents.Google Scholar
  67. 67.
    Saavedra M, Riera L, Bottale A, Mariani M, Maiza A, Ambrosio A. Estabilidad de la vacuna Candid #1 para prevenir la fiebre hemorrágica argentina. Medicina (B Aires). 2017;77:353–7.Google Scholar
  68. 68.
    Pavlakis GN, Felber BK. A new step towards an HIV/AIDS vaccine. Lancet [Internet]. 2018;6736(18):10–1. Available from:  https://doi.org/10.1016/S0140-6736(18)31548-4.CrossRefGoogle Scholar
  69. 69.
    Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet [Internet]. 2018;392(10149):787–90. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618317100.CrossRefGoogle Scholar
  70. 70.
    The Lancet Infectious Diseases. The dengue vaccine dilemma. Lancet Infect Dis [Internet]. 2018;18(2):123. Available from:  https://doi.org/10.1016/S1473-3099(18)30023-9. CrossRefGoogle Scholar
  71. 71.
    Giel-Moloney M, Goncalvez AP, Catalan J, Lecouturier V, Girerd-Chambaz Y, Diaz F, et al. Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine. Sci Rep [Internet]. 2018;8(1):13206. Available from: http://www.nature.com/articles/s41598-018-31375-9.CrossRefGoogle Scholar
  72. 72.
    Touret F, Gilles M, Klitting R, Aubry F, de Lamballerie X, Nougairede A. Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone. bioRxiv [Internet]. 2018:272625. Available from: https://www.biorxiv.org/content/early/2018/02/27/272625.
  73. 73.
    Nami S, Mohammadi R, Vakili M, Khezripour K, Mirzaei H, Morovati H. Fungal vaccines, mechanism of actions and immunology: a comprehensive review. Biomed Pharmacother [Internet]. 2019;109(October 2018):333–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332218353903.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Carlos Pineda
    • 1
  • Carina Soto-Fajardo
    • 1
  • Julio Granados
    • 2
  1. 1.Division of Musculoskeletal and Rheumatic DisordersInstituto Nacional de Rehabilitacion Luis Guillermo Ibarra IbarraMexico CityMexico
  2. 2.Immunogenetics Division, Department of TransplantsInstituto Nacional de Ciencias Medica y Nutricion Salvador ZubiránMexico CityMexico

Personalised recommendations